StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Fate Therapeutics (FATE)

Fri, 10 Jul 2026 06:52:16 -0400

H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating and $7.00 price target on Fate Therapeutics (NASDAQ: FATE).

The analyst commented: "Earlier today, Fate announced that the FDA has cleared its IND application for FT839, a next-generation, off-the-shelf CD19- and CD38-co-targeted. With IND clearance, Fate plans to advance FT839 into a basket clinical trial to evaluate the product candidate across a range of autoimmune diseases when administered in combination with standard-of-care therapy and without reliance on conditioning chemotherapy. Enrollment in the Phase 1/2 study is expected to commence in 2H26. Reiterate Buy rating and $7 PT."

For an analyst ratings summary and

Fate Therapeutics gets FDA clearance for FT839 CAR T-cell candidate

Thu, 09 Jul 2026 08:30:12 -0400

Fate Therapeutics, Inc. (NASDAQ: FATE) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for FT839, a CAR T-cell product candidate engineered to simultaneously target CD19 and CD38.

According to the company's press release, FT839 is designed as an off-the-shelf therapy derived from induced pluripotent stem cells and incorporates 13 targeted genetic edits intended to support immune evasion, multi-antigen targeting, and functional persistence. The candidate is manufactured from a clonal master iPSC bank, which the company says allows for large-scale, uniform production.

With the IND clearance, Fate Therapeutics plans to initiate a Phase 1/2 basket clinical

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

Thu, 09 Jul 2026 08:30:00 -0400

First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development

Novel 13-point edited CAR T cell Built with a Suite of Genetic Edits and Manufactured as a Uniform Drug Product to Support Clinical Safety and Durable Efficacy in Autoimmune and Hematological Malignancies

SAN DIEGO, July 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune disease, today

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

Thu, 09 Jul 2026 08:30:00 -0400

First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development

Form SCHEDULE 13G/A FATE THERAPEUTICS INC Filed by: BlackRock, Inc.

Wed, 08 Jul 2026 11:13:00 -0400

si-local-file:///var/storage/secattach/20260708/26746091.html

Form SCHEDULE 13G/A FATE THERAPEUTICS INC Filed by: BlackRock, Inc.

Wed, 08 Jul 2026 11:13:00 -0400

si-local-file:///var/storage/secattach/20260708/26746091.html

Fate Therapeutics to present FT819 systemic sclerosis data at ISSCR

Mon, 06 Jul 2026 08:31:05 -0400

Fate Therapeutics, Inc. (NASDAQ: FATE) announced it will present preliminary clinical data from its off-the-shelf CAR T-cell product candidate, FT819, at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting in Montréal, Canada, on July 9, 2026.

The presentation will cover data from the systemic sclerosis (SSc) arm of the company's ongoing Phase 1 basket trial, which evaluates FT819 across various autoimmune diseases. The trial enrolls treatment-refractory patients who have experienced prior treatment failure and have ongoing active disease. Eligibility was expanded to include patients with up to 15 years of disease duration.

Data from the first four SSc patients

Fate Therapeutics to present FT819 systemic sclerosis data at ISSCR

Mon, 06 Jul 2026 08:31:05 -0400

Data from the first four SSc patients

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

Mon, 06 Jul 2026 08:30:00 -0400

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune disease, today announced that preliminary clinical data from the Company’s off-the-shelf CAR T-cell product candidate, FT819, will be presented at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting, being held at the Palais des congrès de Montréal in Montréal, Canada on July 8 - 11, 2026.

The Company is participating in the Clinical Trials Update oral

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

Mon, 06 Jul 2026 08:30:00 -0400

The Company is participating in the Clinical Trials Update oral

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

Wed, 01 Jul 2026 16:05:00 -0400

SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) --  Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in the following investor conferences in the third quarter of 2026.

Leerink Partners Therapeutics Forum

Location: Boston, MA

Date: July 14th & 15th

Wells Fargo 21st Annual Healthcare Conference

Location: Boston, MA

Date: September 8th – 10th

12th Annual Cantor Fitzgerald Global Healthcare Conference

Location:

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

Wed, 01 Jul 2026 16:05:00 -0400

Leerink Partners Therapeutics Forum

Location: Boston, MA

Date: July 14th & 15th

Wells Fargo 21st Annual Healthcare Conference

Location: Boston, MA

Date: September 8th – 10th

12th Annual Cantor Fitzgerald Global Healthcare Conference

Location:

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

Wed, 01 Jul 2026 16:05:00 -0400

Leerink Partners Therapeutics Forum

Location: Boston, MA

Date: July 14th & 15th

Wells Fargo 21st Annual Healthcare Conference

Location: Boston, MA

Date: September 8th – 10th

12th Annual Cantor Fitzgerald Global Healthcare Conference

Location:

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

Wed, 01 Jul 2026 16:05:00 -0400

Leerink Partners Therapeutics Forum

Location: Boston, MA

Date: July 14th & 15th

Wells Fargo 21st Annual Healthcare Conference

Location: Boston, MA

Date: September 8th – 10th

12th Annual Cantor Fitzgerald Global Healthcare Conference

Location:

Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: Lee Michael Stewart

Mon, 15 Jun 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260615/26648592.html

Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: Lee Michael Stewart

Mon, 15 Jun 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260615/26648592.html

Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: Redmile Group, LLC

Mon, 15 Jun 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260615/26648602.html

Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: Redmile Group, LLC

Mon, 15 Jun 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260615/26648602.html

Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: Jooss Karin

Mon, 15 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260615/26647403.html

Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: Jooss Karin

Mon, 15 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260615/26647403.html

Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: Xu Yuan

Mon, 15 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260615/26647425.html

Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: Xu Yuan

Mon, 15 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260615/26647425.html

Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: EPSTEIN ROBERT S

Mon, 15 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260615/26647386.html

Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: EPSTEIN ROBERT S

Mon, 15 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260615/26647386.html

Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: Agarwal Shefali

Mon, 15 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260615/26647372.html